Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Cash & Current Investments (2023 - 2026)

Beta Bionics' Cash & Current Investments history spans 4 years, with the latest figure at $30.3 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments fell 86.91% to $30.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $30.3 million, a 86.91% decrease, with the full-year FY2025 number at $219.1 million, up 111.56% from a year prior.
  • Cash & Current Investments hit $30.3 million in Q1 2026 for Beta Bionics, down from $219.1 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for BBNX hit a ceiling of $249.7 million in Q2 2025 and a floor of $13.0 million in Q2 2024.
  • Historically, Cash & Current Investments has averaged $121.2 million across 4 years, with a median of $100.2 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: surged 1816.65% in 2025 and later crashed 86.91% in 2026.
  • Tracing BBNX's Cash & Current Investments over 4 years: stood at $96.7 million in 2023, then increased by 7.06% to $103.6 million in 2024, then soared by 111.56% to $219.1 million in 2025, then crashed by 86.17% to $30.3 million in 2026.
  • Business Quant data shows Cash & Current Investments for BBNX at $30.3 million in Q1 2026, $219.1 million in Q4 2025, and $228.7 million in Q3 2025.